Exicure Inc XCUR
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-05-09 |
| Shares Out. | 6,370,000 |
| Website | exicuretx.com/ โ |
| Phone | 13026365400 |
| Employees | 8 |
| Net Income | -$1.8M |
| Free Cash Flow | -$8.1M |
| Total Assets | $12.8M |
| Total Liabilities | $10.7M |
| Equity | $2.1M |
About Exicure Inc
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Exicure Inc is a publicly traded company under the ticker symbol XCUR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
6 analysts (2023-01-01)

